Shenzhen Weiguang Biological Products Co., Ltd. (SZSE:002880) agreed to acquire 80% stake in Ankang Huitian Plasmapheresis Station Co., Ltd. from Xia Yuzhen for CNY 22.8 million on January 6, 2023. The board of directors of Shenzhen Weiguang Biological Products approved the transaction. Ankang Huitian Plasmapheresis Station recorded total assets of 8.72 million and net liabilities of CNY 0.74 million as of August 31, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.71 CNY | -2.26% | -1.91% | -21.12% |
06-03 | Weiguang Biological Products Gets Nod for Human Prothrombin Complex | MT |
05-20 | Shenzhen Weiguang Biological Products Co., Ltd. Approves Dividend for the Year 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.12% | 885M | |
+2.97% | 94.74B | |
-3.68% | 37.28B | |
-11.86% | 32.68B | |
+74.21% | 27.72B | |
-13.95% | 16.19B | |
-2.17% | 13.88B | |
-12.21% | 11.58B | |
+188.83% | 10.92B | |
-53.94% | 9.54B |
- Stock Market
- Equities
- 002880 Stock
- News Shenzhen Weiguang Biological Products Co., Ltd.
- Shenzhen Weiguang Biological Products Co., Ltd. agreed to acquire 80% stake in Ankang Huitian Plasmapheresis Station Co., Ltd. from Xia Yuzhen for CNY 22.8 million